http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 24 Aug 2026 12:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of July 31, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html Mon, 24 Aug 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of July 31, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html Mon, 24 Aug 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of July 31, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html Mon, 24 Aug 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of July 31, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html Mon, 24 Aug 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of July 31, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html Mon, 24 Aug 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of July 31, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html Mon, 24 Aug 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of July 31, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Press+Releases/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html Mon, 24 Aug 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of July 31, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html Mon, 24 Aug 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of July 31, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html Mon, 24 Aug 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of July 31, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html Mon, 24 Aug 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of July 31, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html Mon, 24 Aug 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of July 31, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html Mon, 24 Aug 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of July 31, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html Mon, 24 Aug 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Pursuant to the provisions of article L. 233-8 II of the French “Code de Commerce” and article 223-16 of the General Regulation of the French stock-market authorities (<i>Autorité des Marchés Financiers</i>, or “AMF”), ADOCIA SA (Paris:ADOC), a French <i>société anonyme</i> (corporation), 115, avenue Lacassagne, 69003 Lyon (Euronext Paris: FR0011184241 – ADOC – the “Company”) a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, releases its total number of outstanding shares as well as its voting rights as of July 31, 2026. </p><table cellspacing="0" http://www.streetinsider.com/Business+Wire/Number+of+Shares+and+Voting+Rights+of+ADOCIA+as+of+July+31st%2C+2026/26966409.html Mon, 24 Aug 2026 12:00:00 -0400 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 http://www.streetinsider.com/Press+Releases/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html <ul class="bwlistdisc"> <li> Cash position of €9.7 million as of June 30, 2026 </li> <li> Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027 </li> <li> BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies </li> </ul> <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update. </p><p> <i>“During the quarter, we http://www.streetinsider.com/Press+Releases/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html Thu, 23 Jul 2026 12:00:00 -0400 A.20822773 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 O.20370956 http://www.streetinsider.com/Press+Releases/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html <ul class="bwlistdisc"> <li> Cash position of €9.7 million as of June 30, 2026 </li> <li> Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027 </li> <li> BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies </li> </ul> <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update. </p><p> <i>“During the quarter, we http://www.streetinsider.com/Press+Releases/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html Thu, 23 Jul 2026 12:00:00 -0400 A.20822773 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 O.20370956 http://www.streetinsider.com/Press+Releases/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html <ul class="bwlistdisc"> <li> Cash position of €9.7 million as of June 30, 2026 </li> <li> Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027 </li> <li> BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies </li> </ul> <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update. </p><p> <i>“During the quarter, we http://www.streetinsider.com/Press+Releases/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html Thu, 23 Jul 2026 12:00:00 -0400 A.20822773 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 O.20370956 http://www.streetinsider.com/Press+Releases/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html <ul class="bwlistdisc"> <li> Cash position of €9.7 million as of June 30, 2026 </li> <li> Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027 </li> <li> BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies </li> </ul> <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update. </p><p> <i>“During the quarter, we http://www.streetinsider.com/Press+Releases/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html Thu, 23 Jul 2026 12:00:00 -0400 A.20822773 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 O.20370956 http://www.streetinsider.com/Press+Releases/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html <ul class="bwlistdisc"> <li> Cash position of €9.7 million as of June 30, 2026 </li> <li> Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027 </li> <li> BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies </li> </ul> <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update. </p><p> <i>“During the quarter, we http://www.streetinsider.com/Press+Releases/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html Thu, 23 Jul 2026 12:00:00 -0400 A.20822773 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 O.20370956 http://www.streetinsider.com/Press+Releases/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html <ul class="bwlistdisc"> <li> Cash position of €9.7 million as of June 30, 2026 </li> <li> Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027 </li> <li> BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies </li> </ul> <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update. </p><p> <i>“During the quarter, we http://www.streetinsider.com/Press+Releases/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html Thu, 23 Jul 2026 12:00:00 -0400 A.20822773 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 O.20370956 http://www.streetinsider.com/Press+Releases/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html <ul class="bwlistdisc"> <li> Cash position of €9.7 million as of June 30, 2026 </li> <li> Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027 </li> <li> BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies </li> </ul> <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update. </p><p> <i>“During the quarter, we http://www.streetinsider.com/Press+Releases/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html Thu, 23 Jul 2026 12:00:00 -0400 A.20822773 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 O.20370956 http://www.streetinsider.com/Press+Releases/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html <ul class="bwlistdisc"> <li> Cash position of €9.7 million as of June 30, 2026 </li> <li> Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027 </li> <li> BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies </li> </ul> <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update. </p><p> <i>“During the quarter, we http://www.streetinsider.com/Press+Releases/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html Thu, 23 Jul 2026 12:00:00 -0400 A.20822773 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 O.20370956 http://www.streetinsider.com/Press+Releases/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html <ul class="bwlistdisc"> <li> Cash position of €9.7 million as of June 30, 2026 </li> <li> Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027 </li> <li> BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies </li> </ul> <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update. </p><p> <i>“During the quarter, we http://www.streetinsider.com/Press+Releases/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html Thu, 23 Jul 2026 12:00:00 -0400 A.20822773 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 O.20370956 http://www.streetinsider.com/Business+Wire/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html <ul class="bwlistdisc"> <li> Cash position of €9.7 million as of June 30, 2026 </li> <li> Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027 </li> <li> BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies </li> </ul> <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update. </p><p> <i>“During the quarter, we http://www.streetinsider.com/Business+Wire/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html Thu, 23 Jul 2026 12:00:00 -0400 A.20822773 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 O.20370956 http://www.streetinsider.com/Business+Wire/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html <ul class="bwlistdisc"> <li> Cash position of €9.7 million as of June 30, 2026 </li> <li> Shareholder loan agreement signed with Vester Finance in April 2026, securing a cash runway until the beginning of Q2 2027 </li> <li> BioChaperone® feasibility studies with positive results enabling to engage in discussions for the next steps with large pharmaceutical companies </li> </ul> <p> LYON, France--(BUSINESS WIRE)-- Regulatory News: </p><p> Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, reports financial results for the second quarter of 2026 and provides a business update. </p><p> <i>“During the quarter, we http://www.streetinsider.com/Business+Wire/ADOCIA+Reports+Second+Quarter+2026+Financial+Results+and+Provides+a+Business+Update/26806774.html Thu, 23 Jul 2026 12:00:00 -0400 A.20822773 A.26800952 ADOC ADOCY FR00111842 FR00111842 O.00711722 O.03559126 O.20370956